Please assess the completion status of the following clinical trial:

Trial Title: AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with AML, except those with APL (acute promyelocytic leukemia), failing a single standard dose cytarabine based frontline induction regimen. The diagnosis of refractory AML is based on the presence of either \> 10% blasts in marrow or blood or 5-10% blasts in either site together with cytopenia (Hb \< 10 g/dL, or platelets \< 100 x 109/L, or neutrophil count \< 1.0 x 109/L).~* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.~* Male, or female patients who are post-menopausal (amenorrheic for at least 12 months), or surgically or biologically sterile.~* Patients must have adequate organ and immune function as indicated by the following laboratory values:~Parameter Laboratory Values Serum creatinine; ≤2.0 mg/dL (≤ 177 μmol/L Total Bilirubin ≤2.0 mg/dL (≤ 34 μmol/L) AST (SGOT) and ALT (SGPT) ≤3 X ULN~* The patient must understand, be able and willing and likely to fully comply with study procedures, including scheduled follow-up, and restrictions.~Exclusion Criteria:~* Clinical evidence of ongoing grade 3 or 4 non-hematological toxicities from the initial standard dose cytarabine-based induction chemotherapy~* Patients with a prior history of peripheral neuropathy of grade 2 or higher.~* Clinical evidence of active CNS leukemic involvement.~* Active and uncontrolled infection. Patients with an infection who are under active treatment with antibiotics and whose infections are controlled may be entered to the study.~* Current evidence of invasive fungal infection (blood or tissue culture).~* Current evidence of an active second malignancy except for non-melanoma skin cancer.~* Uncontrolled medical problems, unrelated to the malignancy, or of sufficient severity that in the opinion of the investigator, impair a patient's ability to give informed consent or unacceptably reduce the safety of the proposed treatment.~* Neurological or psychiatric disorders that would interfere with consent or study follow-up.~* Known or suspected intolerance or hypersensitivity to the study drugs \[or closely related compounds\] or any of their stated ingredients. Study drugs being the antisense, cytarabine and idarubicin.~* History of alcohol or other substance abuse within the last year.~* Use of another investigational agent within the last 14 days prior to enrolment. Patients who have received a previous antisense agent in the last 90 days will be excluded.~* Female patients who are pregnant, lactating, or with a positive pregnancy test at screening must be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AEG35156 (Type: ACTIVE_COMPARATOR): Patient receive AEG35156 prior to chemotherapy
- Control (Type: SHAM_COMPARATOR): Patients receive chemotherapy only

Based on this trial design, predict the completion outcome and termination type (if applicable).